Valbenazine Tosylate

Valbenazine Tosylate

一、Product Overview

      Valbenazine, developed by Neurocrine Biosciences for the treatment of adult - tardive dyskinesia and chorea associated with Huntington’s disease., was approved by the Food and Drug Administration (FDA) on April 11, 2017 and its patent expires in 2029.

二、Main Product

Description	Structural Formula	CAS No.	Category
Valbenazine Tosylate		1639208-54-0	API
2-acetyl-N,N,N,4-tetramethylpentan-1- aminium iodide		1069-62-1	Intermediate
6,7-dimethoxy-3,4-dihydroisoquinoline hydrochloride		20232-39-7	Intermediate
(S)-2-((tert-butoxycarbonyl)amino)-3-methylbutanoic acid		13734-41-3	Intermediate

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement and its liability is at buyer's risk.